PEGylation is the covalent coupling of non-toxic, hydrophilic polyethylene glycol (PEG) to dynamic pharmaceutical elements such as proteins, peptides, antibodies, colloids and others. PEGylation is routinely accomplished by incubation of a reactive derivative of PEG with the target molecule. PEGylation raises strength and solubility of the drug and decreases immunogenicity by changing the electrostatic binding, confirmation, and hydrophobicity of the particle. The rise in adoption of PEGylation to treat various chronic diseases and the applications in PEGylation is the key factor that is driving the PEGylation market. PEGylation market was valued at a revenue of $XXm in 2016 and is estimated to reach $XXm in 2022 with an anticipated growth at a CAGR of XX% during 2017-2022.
PEGylation is the process of suitable functionalization of the PEG polymer at one or both terminals. PEGs that are actuated at every end with the same responsive half are known as "homobifunctional", though if the useful gatherings present are distinctive, then the PEG derivative is referred as "heterofunctional." The chemically dynamic or activated derivatives of the PEG polymers are set up to attach the PEG to the desired molecule. PEGylated proteins have wide applications and preferences over traditional treatment, as a result, the adoption is high. Failure of drug development and recall of products are the factors which will affect the PEGylated proteins market.
PEGylated proteins market is divided into four different geographic regions. North America and Europe are the major markets for PEGylated proteins. Countries in these regions are well developed and patients are very conscious about the diseases and available treatments. Increasing prevalence of chronic diseases and rise in health care spending are expected to drive the market in Asia-Pacific.
Sample Companies Profiled in this Report are:
- Merck Millipore (U.S.),
- NOF Corporation (Japan),
- Celares GmbH (Germany),
- Biomatrik, Inc, (China),
- Thermo Fisher Scientific, Inc. (U.S.)